Abstracts tagged "Cardiovascular disease and psoriatic arthritis"

Abstract Number: 2827 • 2018 ACR/ARHP Annual Meeting
Remission Targets and Prevention of Subclinical Atherosclerosis in Psoriatic Arthritis- Which Target Should We Choose?
Isaac T. Cheng¹, Qing Shang², Edmund Kwok Ming Li², Priscilla Wong¹, Lydia Ho Pui Tam², Tracy Y. Zhu³, M Mimi Chang⁴, JW Jack LEE⁵, PW Alex Lee² and Lai-Shan Tam⁴, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Bone Quality and Health Centre of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁴Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Biostatistics Division, School of Public and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Systemic inflammation contributes to the excess risk of cardiovascular disease (CVD) in PsA. We had demonstrated that achieving sustained minimal disease activity (sMDA) was…
Abstract Number: 332 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study)
Zohair Abbas¹ and Marina N. Magrey², ¹Rheumatology, Case Western Reserve University at Metrohealth Medical Center, Cleveland, OH, ²Department of Medicine, Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Both patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are at increased risk of cardiovascular disease (CVD). This increased risk is in part…
Abstract Number: 2215 • 2012 ACR/ARHP Annual Meeting
Assessment of Vascular Age in Psoriatic Arthritis Patients
Jl Rosales-Alexander¹, César Magro Checa¹, Juan Salvatierra¹, Jesús Cantero Hinojosa² and Enrique Raya Álvarez¹, ¹Rheumatology, University Hospital San Cecilio, Granada, Spain, ²Internal Medicine, University Hospital San Cecilio, Granada, Spain
Background/Purpose: The European League Against Rheumatism (EULAR) recommends cardiovascular risk (CV) assessment using the systematic coronary risk evaluation (SCORE) chart in inflammatory arthritis patients. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].